卒中溶栓患者使用SSRI与脑出血及结局的关系
SSRI使用与溶栓后症状性脑出血(sICH)无显著关联,但与3个月不良结局相关;同时使用SSRI与口服抗凝药(OAC)的患者sICH风险显著升高。
要点
- 入院前使用SSRI与溶栓后sICH无显著独立关联(调整OR 1.30,95%CI 0.71-2.40)。
- SSRI合并OAC(INR<1.7)时sICH风险显著增加(调整OR 9.04,95%CI 1.95-41.89)。
- 入院前SSRI使用与3个月不良结局相关(调整OR 1.59,95%CI 1.15-2.19)。
核心结论
- 入院前使用SSRI与溶栓后sICH风险无显著独立关联。
- 亚组分析提示SSRI与OAC联合使用时sICH风险显著升高。
- SSRI使用与3个月不良结局相关,可能反映卒中前抑郁的预后意义。
研究设计与样本
- 多中心回顾性分析,基于前瞻性登记数据库。
- 平均年龄70.1±14.0岁,NIHSS中位数9(5-16)。
主要发现
- 入院前SSRI使用率4.3%(n=266)。
- 总体sICH发生率3.9%(95%CI 3.5%-4.4%,n=244)。
- SSRI与sICH的未调整OR 1.28(95%CI 0.72-2.27),调整后OR 1.30(95%CI 0.71-2.40)。
- SSRI与OAC对sICH存在显著交互作用(P=0.01);两者联用时sICH发生率23.1%(95%CI 8.2%-50.3%),调整OR 9.04(95%CI 1.95-41.89)。
- SSRI使用与3个月不良结局相关(未调整OR 1.90,95%CI 1.48-2.46;调整OR 1.59,95%CI 1.15-2.19)。
关键数值与推荐
- sICH采用ECASS II定义。
- 不良结局定义为3个月改良Rankin量表>2。
- OAC交互分析限定INR<1.7。
临床怎么用
- 对溶栓患者应询问入院前SSRI使用史及合并OAC情况。
- SSRI合并OAC(INR<1.7)时需警惕sICH风险升高。
- SSRI使用者的不良结局风险可能与卒中前抑郁相关,需综合评估。
局限性
- 回顾性研究设计,可能存在残余混杂。
- SSRI合并OAC亚组样本量小,置信区间宽。
- 原文未报告亚组具体样本量及抑郁严重程度数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage-an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. METHODS: A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4.5 hours of stroke onset. The association between preadmission treatment with SSRIs and sICH (ECASS II definition [European Cooperative Acute Stroke Study]) or unfavorable 3-month outcome (modified Rankin Scale >2) was assessed by logistic regression, taking into account potential interaction with concomitant use of antithrombotics. RESULTS: Six thousand two hundred forty-two patients were included (mean age, 70.1±14.0 years; median National Institutes of Health Stroke Scale, 9 [5-16]). Preadmission treatment with SSRIs was present in 4.3% (n=266) of patients. Overall, SICH rate was 3.9% (95% confidence interval [CI], 3.5%-4.4%; n=244), and SSRI use was not significantly associated with sICH in unadjusted (odds ratio [OR], 1.28; 95% CI, 0.72-2.27) or adjusted (OR, 1.30; 95% CI, 0.71-2.40) analysis. However, there was a significant interaction of concomitant use of OACs (international normalized ratio <1.7) and SSRI for occurrence of sICH (P=0.01). SICH was significantly more frequent in patients taking both OAC and SSRI (23.1%; 95% CI, 8.2%-50.3%) than in patients taking OAC but not SSRI (adjusted OR, 9.04; 95% CI, 1.95-41.89). Preadmission use of SSRI was associated with unfavorable 3-month outcome (unadjusted OR, 1.90; 95% CI, 1.48-2.46; adjusted OR, 1.59; 95% CI, 1.15-2.19). CONCLUSIONS: Preadmission treatment with SSRIs was not significantly associated with an increased risk of post-thrombolysis sICH in this cohort study. However, subgroup analysis suggested an increased risk of sICH in patients taking both SSRI and OAC. Preadmission treatment with SSRIs was associated with unfavorable outcome, which may reflect the prognostic significance of prestroke depression.
引用
- Scheitz JF, Turc G, Kujala L, et al. Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors. Stroke. 2017. PMID: 29127269. doi:10.1161/STROKEAHA.117.018377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。